CEACAM5 and colorectal cancer: Although colorectal cancer morbidity and mortality are high, universal screening using biomarkers, such as a carcinoembryonic antigen or clinical tests (eg., flexible sigmoidoscopy, colonoscopy, fecal occult blood testing or computed tomographic colonography) is not feasible.